Clinical Trials Logo

Rosacea clinical trials

View clinical trials related to Rosacea.

Filter by:

NCT ID: NCT03478436 Completed - Rosacea Clinical Trials

Pharmacokinetics of Doxycycline in Skin of Healthy Volunteers

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This study explored the impact of food on skin and plasma pharmacokinetics of doxycycline

NCT ID: NCT03472859 Completed - Rosacea Clinical Trials

Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The goal is to compare a novel yellow laser, based on semiconductor technology, with traditional green laser, in the treatment of cheek telangiectasias. The trial design is randomized split-face double-blinded study with 20-30 volunteers. The improvement will be assessed using a 7-point Telangiectasia Grading Scale.

NCT ID: NCT03448939 Completed - Clinical trials for Papulopustular Rosacea

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Start date: June 18, 2018
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.

NCT ID: NCT03424304 Completed - Rosacea Clinical Trials

Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment

Start date: November 6, 2017
Phase: N/A
Study type: Interventional

Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array (MLA) Attachment

NCT ID: NCT03418610 Completed - Clinical trials for Rosacea, Papulopustular

Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea

Start date: December 6, 2017
Phase: Phase 4
Study type: Interventional

This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.

NCT ID: NCT03392558 Completed - Rosacea Clinical Trials

The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

This study evaluates a nature-based sensitive skin regimen (NBSSR), as a suitable adjunct topical application to prescription medication when administered daily over the course of four weeks, in moderate to severe rosacea in comparison to the control regimen (CR).

NCT ID: NCT03380390 Completed - Rosacea Clinical Trials

Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

Start date: December 4, 2017
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.

NCT ID: NCT03352323 Completed - Rosacea Clinical Trials

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

Start date: October 18, 2017
Phase: Phase 3
Study type: Interventional

the study will measure the decrease in redness on the face of rosacea subjects

NCT ID: NCT03340961 Completed - Rosacea Clinical Trials

A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules

Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

Clinical assessments of efficacy will be conducted based on Investigator's Global Assessment (IGA, modified scale without erythema), Clinician's Erythema Assessment (CEA), and on inflammatory lesion counts at Weeks 4, 8, 12 and 16 in comparison to Baseline.

NCT ID: NCT03287791 Completed - Rosacea Clinical Trials

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

Start date: July 19, 2016
Phase: Phase 3
Study type: Interventional

The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of the two active foams in the treatment of moderate facial rosacea, and to demonstrate superiority of the Reference and Test products over the Vehicle.